Home › Kanser sa Dugo › New York › New York City
Pag-aaral pangklinika para sa Kanser sa Dugo sa New York City, NY
26 pag-aaral para sa Kanser sa Dugo ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng New York City (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Nagre-recruitPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Nagre-recruitPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0032), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Nagre-recruitPhase 1
- NYU Langone Health, New York
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Mount Sinai Medical Center, New York
Genomic Profiling in Cancer Patients
Nagre-recruitObservasyonal na pag-aaral
- Metropolitan Hospital Center, New York
- Ralph Lauren Center for Cancer Care and Prevention, New York
- Memorial Sloan Kettering Cancer Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- David H. Koch Center for Cancer Care, New York
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Nagre-recruitPhase 1/2
- Research Site, New York
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Nagre-recruitPhase 3
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University, New York
- Weill Cornell Medical Center, New York
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College-NY Presbyterian Hospital, New York
Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- NYP/Weill Cornell Medical Center, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Nagre-recruitObservasyonal na pag-aaral
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital at Cornell, New York
- Mount Sinai Medical Center - New York, New York
- at 3 pa
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Nagre-recruitPhase 2
- New York University (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
IVIG for Infection Prevention After CAR-T-Cell Therapy
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center, New York
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Nagre-recruitPhase 3
- New York Presbyterian Hospital, New York
- Mt Sinai Medical Center, New York
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
Nagre-recruitObservasyonal na pag-aaral
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Nagre-recruitPhase 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- New York - Presbyterian / Weill Cornell Medicine, New York
- Mount Sinai - Ruttenberg Treatment Center, New York
- Columbia University Medical Center, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Nagre-recruitObservasyonal na pag-aaral
- Memorial Sloan Kettering Cancer Center, New York
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Nagre-recruitPhase 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Nagre-recruitPhase 1/2
- Memorial Sloan Kettering Cancer Center (MSKCC), New York
Pag-aaral para sa Kanser sa Dugo sa ibang lungsod
- Houston, TX46 pag-aaral
- Boston, MA25 pag-aaral
- Washington, DC19 pag-aaral
- Seattle, WA18 pag-aaral
- Baltimore, MD18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Durham, NC16 pag-aaral
- Chicago, IL15 pag-aaral
- Philadelphia, PA14 pag-aaral
- Nashville, TN13 pag-aaral
- Edison, NJ13 pag-aaral
- Columbus, OH13 pag-aaral
Iba pang pag-aaral sa New York City
- Kanser sa Suso136 pag-aaral
- Non-Small Cell Lung Cancer121 pag-aaral
- Kanser (lahat ng uri)109 pag-aaral
- Kanser sa Prostate103 pag-aaral
- Metastatic Cancer93 pag-aaral
- Colorectal Cancer78 pag-aaral
- Kanser sa Ovary69 pag-aaral
- Kanser sa Baga60 pag-aaral
- Multiple Myeloma60 pag-aaral
- Kanser sa Pancreas60 pag-aaral
- Kanser ng Endometrium52 pag-aaral
- Acute Myeloid Leukemia51 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.